By Christian Hayden and Laura Farmer
It may shock you to learn that KRAS, the much-venerated drug target whose success reached a crescendo this year with daraxonrasib’s swift approval, was once considered undruggable. Yes, you heard it here first, and in none of the other 10,000 articles written about KRAS.
Undruggable. Then KRAS G12C inhibitors like sotorasib and adagrasib upended that narrative, establishing direct KRAS inhibition as a viable therapeutic strategy. Now, results from ESMO 2026 suggest that the next generation can deliver substantial improvements over the G12C vanguard. As Roche’s divarasib establishes a new benchmark for KRAS G12C inhibition, an emerging class of RAS(ON) inhibitors raises a larger question: will the future of KRAS-targeted therapy be defined by better drugs within the existing mechanism, or by a fundamentally different approach?
The Phase 3 KRASCENDO-1 trial provided compelling evidence for divarasib in previously treated KRAS G12C-mutated non-small cell lung cancer. Compared with sotorasib or adagrasib, divarasib significantly improved median progression-free survival (9.8 vs. 5.7 months), median overall survival (17.7 vs. 12.0 months), and objective response rate (58.4% vs. 32.3%). Grade 3–4 treatment-related adverse events were also less frequent (24.6% vs. 34.5%), although gastrointestinal toxicity remains a concern.
The results generated widespread enthusiasm among onco KOLs, with many describing the findings as practice-changing. Some went so far as to suggest that divarasib could effectively displace existing KRAS G12C inhibitors once approved. One important caveat: approximately 91% of patients in the comparator arm received sotorasib, leaving considerable uncertainty about divarasib’s relative performance against adagrasib specifically. But even with that caveat, divarasib has demonstrated that the established KRAS(OFF) approach is still capable of delivering major clinical advances.
But is that enough?
Two Approaches to Targeting KRAS
Divarasib, like sotorasib and adagrasib, is a KRAS(OFF) inhibitor. These therapies bind the inactive, GDP-bound form of KRAS G12C, preventing its reactivation and suppressing downstream oncogenic signaling.
Meanwhile, a different approach is advancing through clinical development. RAS(ON) inhibitors target the active, GTP-bound state of RAS, potentially offering an alternative way to suppress oncogenic signaling and address certain mechanisms of resistance to existing therapies.
Revolution Medicines’ elironrasib is among the most relevant emerging competitors. Unlike divarasib, elironrasib targets KRAS G12C in its active state and has demonstrated preliminary activity in patients previously treated with KRAS(OFF) inhibitors. In an early cohort of 24 heavily pretreated patients, 92% of whom had progressed on prior KRAS(OFF) therapy, elironrasib demonstrated encouraging antitumor activity. Although these findings remain preliminary, they suggest a potential role for RAS(ON) inhibition after progression on existing targeted treatments.
The plot thickens. The emerging competition isn’t simply between active- and inactive-state inhibition. It’s also between drugs designed for specific KRAS mutations and broader approaches capable of targeting multiple RAS variants. Daraxonrasib, for instance, is a multi-selective RAS(ON) inhibitor whose development extends beyond G12C, while zoldonrasib selectively targets KRAS G12D. Meanwhile, pan-KRAS and pan-RAS approaches could expand targeted treatment to patients whose mutations currently lack effective options.
This introduces another competitive dimension: the potential trade-off between the precision of mutation-selective inhibitors and the broader reach of multi-selective therapies. Broader inhibition could expand the addressable population and potentially suppress additional resistance pathways, but their broader activity also raises important questions about selectivity, tolerability, and therapeutic index.
These agents are not all direct competitors to divarasib. Rather, they illustrate how the KRAS landscape is evolving beyond competition between individual G12C inhibitors toward a wider range of mechanisms, mutation profiles, and therapeutic strategies.
So What’s Next?
The next phase of KRAS drug development may be defined as much by treatment setting as by mechanism. For KRAS(OFF) inhibitors, the immediate opportunity is moving into earlier lines of treatment. Roche’s KRASCENDO-2 is evaluating divarasib plus pembro in first-line NSCLC, while Lilly’s SUNRAY-01 and Merck’s KANDLELIT program are investigating combinations involving olomorasib and calderasib, respectively. These studies could establish whether the benefits of KRAS inhibition can be extended beyond previously treated patients.
The first-line race is particularly consequential. Divarasib’s success in KRASCENDO-1 could establish it as the preferred option for patients who have not previously received a KRAS G12C inhibitor. But as targeted therapies move earlier in treatment, that second-line, inhibitor-naive population could shrink. The eventual commercial success of KRASCENDO-1 could therefore hinge on which agents establish themselves in first line, and whether subsequent KRAS inhibition remains effective after progression.
For RAS(ON) inhibitors, the opportunities are potentially broader. Activity following KRAS(OFF) inhibitor exposure could create a distinct role in treatment sequencing, while successful first-line combinations might eventually position these agents as direct competitors to KRAS(OFF) therapies.
However, RAS(ON) inhibitors may not have the post-progression setting to themselves. Next-generation KRAS(OFF) agents are also showing activity after prior G12C inhibition. D3 Bio’s elisrasib, for example, demonstrated a 32.3% response rate and median progression-free survival of 8.1 months in a Phase 1/2 cohort previously treated with a KRAS G12C inhibitor. While cross-trial comparisons are dicey, the findings suggest that overcoming resistance may not require abandoning the KRAS(OFF) mechanism altogether.
This creates an intriguing possibility: rather than one mechanism simply replacing the other, KRAS(OFF) and RAS(ON) inhibitors could ultimately occupy complementary positions within the treatment pathway. But that outcome is far from certain. If RAS(ON) inhibitors demonstrate superior efficacy or tolerability in earlier-line randomized trials, they could challenge KRAS(OFF) therapies directly. Divarasib’s success, meanwhile, demonstrates that the established mechanism remains a formidable competitor.
Important questions also remain around CNS activity, resistance mechanisms, and the safety of combinations with immunotherapy. These factors may prove just as consequential as the distinction between active- and inactive-state inhibition.
The Next Chapter
KRASCENDO-1 represents a major advance for patients with KRAS G12C-mutated NSCLC and a significant competitive achievement for Roche. But its implications extend well beyond the immediate competition between KRAS G12C inhibitors.
The first generation of KRAS inhibitors demonstrated that a historically difficult target could be drugged. Divarasib has now shown that substantial improvements are possible within an established mechanism. The emerging RAS(ON) pipeline will test whether targeting the active state of RAS can deliver further benefits, overcome resistance, or expand the population eligible for targeted treatment.